毕得医药：股东欣曦管理、兰旦管理及其一致行动人吴波计划减持公司股份

Group 1 - Bid Pharma announced that as of the disclosure date, shareholder Zhoushan Xinxie Enterprise Management Partnership holds approximately 4.72 million unrestricted shares, accounting for 5.19% of the total shares [1] - Shareholder Zhoushan Landan Enterprise Management Partnership holds about 3.58 million shares, representing 3.94% of the total shares, with approximately 6.95 thousand shares being restricted and about 3.51 million shares being unrestricted [1] - Shareholder Wu Bo holds approximately 785.8 thousand unrestricted shares, which is 0.86% of the total shares [1] Group 2 - Xinxie Management, Landan Management, and Wu Bo are acting in concert, collectively holding 10% of Bid Pharma's shares [1] - Due to liquidity needs, these shareholders plan to reduce their holdings within three months after the disclosure of the reduction plan, starting 15 trading days from the announcement [1] - Xinxie Management plans to reduce up to approximately 1.0361 million shares through block trading and up to approximately 363.5 thousand shares through centralized bidding, while Landan Management and Wu Bo have similar reduction plans [1]